The Prognostic Value of PI-RADS Score in CyberKnife Ultra-Hypofractionated Radiotherapy for Localized Prostate Cancer.
Pi-Rads
metastasis-free survival
prognosis
prostate cancer
radiotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Mar 2022
23 Mar 2022
Historique:
received:
19
02
2022
revised:
16
03
2022
accepted:
17
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Prostate Imaging-Reporting and Data System (PI-RADS) has been widely implemented as a diagnostic tool for significant prostate cancer (PCa); less is known about its prognostic value, especially in the setting of primary radiotherapy. We aimed to analyze the association between PI-RADS v. 2.1 classification and risk of metastases, based on a group of 152 patients treated with ultra-hypofractionated stereotactic CyberKnife radiotherapy for localized low or intermediate risk-group prostate cancer. We found that all distant failures (n = 5) occurred in patients diagnosed with a PI-RADS score of 5, and axial measurements of the target lesion were associated with the risk of developing metastases (p < 0.001). The best risk stratification model (based on a combination of greatest dimension, the product of multiplication of PI-RADS target lesion axial measurements, and age) achieved a c-index of 0.903 (bootstrap-validated bias-corrected 95% CI: 0.848−0.901). This creates a hypothesis that PI-RADS 5 and the size of the target lesion are important prognostic factors in early-stage PCa patients and should be considered as an adverse prognostic measure for patients undergoing early treatment such as radiation or focal therapy.
Identifiants
pubmed: 35406385
pii: cancers14071613
doi: 10.3390/cancers14071613
pmc: PMC8997034
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur Radiol. 2016 Aug;26(8):2502-9
pubmed: 26560721
Korean J Radiol. 2019 Feb;20(2):256-264
pubmed: 30672165
Urol Oncol. 2020 Jun;38(6):600.e1-600.e8
pubmed: 31953005
Stat Med. 2011 May 10;30(10):1105-17
pubmed: 21484848
AJR Am J Roentgenol. 2019 Mar 27;:1-8
pubmed: 30917023
Eur Urol. 2019 Sep;76(3):340-351
pubmed: 30898406
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
J Urol. 2021 Sep;206(3):507-516
pubmed: 33904755
Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):57-66
pubmed: 9989514
Eur Urol Open Sci. 2020 Jul;20:37-47
pubmed: 33000006
FASEB J. 2020 Nov;34(11):14150-14159
pubmed: 32920937
Eur Urol. 2019 Jul;76(1):18-23
pubmed: 30685078
Eur Urol Oncol. 2020 Dec;3(6):739-747
pubmed: 32847747
Prostate Int. 2021 Mar;9(1):6-11
pubmed: 33912508
Theranostics. 2021 Jul 6;11(16):8027-8042
pubmed: 34335978
Radiother Oncol. 2018 Apr;127(1):49-61
pubmed: 29496279
J Urol. 2013 Jan;189(1):99-104
pubmed: 23164377
Eur Radiol. 2019 Sep;29(9):4861-4870
pubmed: 30847589
J Magn Reson Imaging. 2017 Feb;45(2):586-596
pubmed: 27654116
Radiology. 2015 Dec;277(3):741-50
pubmed: 26098458
Eur J Radiol. 2020 Jul;128:109020
pubmed: 32371181
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819870815
pubmed: 31462169
J Magn Reson Imaging. 2019 Feb;49(2):546-555
pubmed: 30187600
Eur Urol. 2019 Mar;75(3):385-396
pubmed: 29908876
Urol Oncol. 2018 Oct;36(10):471.e11-471.e18
pubmed: 30122344
J Urol. 2022 Feb;207(2):350-357
pubmed: 34547922
Cancer Radiother. 2016 Jun;20(4):275-81
pubmed: 27342944
J Urol. 2018 May;199(5):1218-1223
pubmed: 29128577
Magn Reson Imaging. 2019 Jul;60:76-84
pubmed: 30917943
J Urol. 2018 Sep;200(3):564-572
pubmed: 29524506
J Clin Epidemiol. 2017 Mar;83:75-84
pubmed: 28088594
Acta Oncol. 2014 Jun;53(6):809-14
pubmed: 24358954
Strahlenther Onkol. 2011 Mar;187(3):183-90
pubmed: 21347638
Clin Genitourin Cancer. 2018 Aug;16(4):e817-e829
pubmed: 29576444
Turk J Urol. 2019 Jul 1;45(4):237-244
pubmed: 31291186
Lancet Oncol. 2021 Mar;22(3):402-410
pubmed: 33662287